prospectus is                     , 2016.Table of ContentsTABLE OF CONTENTSPROSPECTUS SUMMARY1RISK FACTORS12SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS48MARKET, INDUSTRY AND OTHER DATA49USE OF PROCEEDS50DIVIDEND POLICY51CAPITALIZATION52DILUTION54SELECTED CONSOLIDATED FINANCIAL DATA57MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS59BUSINESS77MANAGEMENT124EXECUTIVE COMPENSATION129CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS142PRINCIPAL STOCKHOLDERS146DESCRIPTION OF CAPITAL STOCK148SHARES ELIGIBLE FOR FUTURE SALE151MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS153UNDERWRITING157LEGAL MATTERS164EXPERTS164WHERE YOU CAN FIND MORE INFORMATION164INDEX TO FINANCIAL STATEMENTSF-1We have not, and the underwriters have not, authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing
In that event, the trading price of our common stock could decline, and you may lose part or all of your investment.Risks Related to the Development, Regulatory Approval and Commercialization of our Current and Future Product CandidatesDrug development involves a lengthy and expensive process with uncertain outcomes, and results from earlier studies and trials may not be predictive of future trial results.Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain.
other available therapies, including any new drugs that may be approved for the indications we are investigating;•our ability to obtain patient consents; and•the risk that patients enrolled in clinical trials will drop out of the trials before completion.In addition, our clinical trials will compete for the recruitment of patients with other clinical trials for product candidates that are
terminate our clinical trials at any time, for various reasons, including the discovery of serious or unexpected toxicities or other safety issues experienced by trial participants.In addition, adverse events caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive
maintaining market acceptance of the particular product candidate, if approved, and may result in the loss of significant revenues to us, which would materially and adversely affect our results of operations and business.The regulatory approval processes of the FDA are lengthy, time-consuming and inherently unpredictable, and if we are ultimately unable
risks;•the FDA’s requirement for additional preclinical studies or clinical trials;•the FDA’s disagreement regarding the formulation, labeling or the specifications of our product candidates;15Table of Contents•the FDA’s agency’s failure to approve the manufacturing processes or facilities of third-party manufacturers with which we
obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies, which is time-consuming and costly.
economically challenging times;•the revenue and profitability that our product candidates may offer a physician as compared to alternative therapies;•the prevalence and severity of adverse events;•limitations or warnings contained in the FDA-approved labeling for our product candidates;•any FDA requirement to undertake a REMS;•the effectiveness of our sales, marketing and distribution efforts;•adverse publicity about our product candidates or favorable publicity about competitive products; and•potential product liability claims.If any of our current or future product candidates are approved for use but fail to achieve the broad degree of physician and patient adoption necessary for commercial success, our
may be more limited than the purposes for which a product is approved by the FDA or similar regulatory authorities outside the United States.Assuming that we obtain coverage for a given product, the resulting reimbursement rates might not be adequate to cover our costs, including research, development, manufacture, sale and
for which we may receive regulatory approval may not be available, limited, or adequate in either the United States or international markets.We may face product liability exposure, and if successful claims are brought against us, we may incur substantial liability if our insurance coverage for those claims is inadequate.We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face
In addition, regardless of merit or eventual outcome, product liability claims may result in:•withdrawal of clinical trial participants;•decreased enrollment rates of clinical trial participants;21Table of Contents•termination of clinical trial sites or entire trial programs;•the inability to commercialize our product candidates;•decreased demand for our product candidates;•impairment of our business reputation;•product recall or withdrawal from the market or labeling, marketing or promotional restrictions;•substantial costs of any related litigation or similar disputes;•distraction of management’s attention and other resources from our primary business;•substantial monetary awards to patients or other claimants against us that may not be covered by insurance; or•loss of revenue.We have obtained product liability insurance coverage, with an aggregate limit of $5.0 million, for clinical trials.
As a result we may not be able to obtain regulatory approval in a timely fashion, or at all, for the applicable product24Table of Contentscandidate, our financial results and the commercial prospects for our product candidates would be harmed, our costs could increase, and our ability to generate revenues could be delayed.In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time
If securities analysts or investors perceive those results to be negative, it could cause the price of shares of our common stock to decline.We may not be able to protect our intellectual property rights throughout the world, which could impair our business.Filing, prosecuting and defending patents on our product candidates in all countries throughout the world would be prohibitively
the net proceeds of this offering, prior to the commercialization of SB204 to fund any commercialization efforts in anticipation of regulatory approval of SB204.Our future capital requirements will depend on many factors, including:•clinical trials for SB204, SB206 and SB208;•the scope, progress, results and costs of preclinical development, laboratory testing and clinical trials for our other product
Any of the above could result in delays in the regulatory approval, manufacture, distribution or commercialization of our product candidates.Risks Related to Our Common Stock and this OfferingAfter this offering, our executive officers, directors and principal stockholders, if they choose to act together, will continue to